PT-CD16VS / Celularity - LARVOL DELTA

Placental circulating T cells expressing CD16 in combination with trastuzumab demonstrate robust anti-tumor antibody-dependent cellular cytotoxicity (ADCC) against gastric cancer (AACR 2024) - "In vivo, PT-CD16VS with Trastuzumab demonstrated significant reduction in tumor volume compared to vehicle, Trastuzumab alone, and the positive control Enhertu groups. Our results show that PT-CD16VS has robust in vitro and in vivo ADCC activity against gastric cancer tumor cells when combined with Trastuzumab. Furthermore, PT-CD16VS activity is specific to tumor HER2 antigen expression and does not target low HER2 expression on normal healthy cells. PT-CD16VS is being developed in combination with various monoclonal antibodies for the treatment of multiple cancers."

ADC • Combination therapy • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies. (ASCO 2024) - "In vitro, PT-CD16VS exhibited potent ADCC and cytokine release when combined with Rituximab against CD20+ Burkitt's lymphoma (Daudi and Raji), with Trastuzumab against HER2+ gastric carcinoma (NCI-N87), with Trastuzumab or Avelumab against HER2+/PDL-1+ non-small cell lung carcinoma (NCI-H1975) and Trastuzumab-resistant metastatic mammary adenocarcinoma (JIMT-1), and with Cetuximab against EGFR+ triple negative metastatic mammary adenocarcinoma (MDA-MB-231)...In the subcutaneous NCI-N87 solid tumor model, PT-CD16VS with Trastuzumab demonstrated significant reduction in tumor volume compared to vehicle, Trastuzumab, and Enhertu groups... Our results show that PT-CD16VS have potent in vitro and in vivo ADCC activity, and a single drug product has the potential to be combined with various monoclonal antibodies to target multiple cancers across hematological and solid tumor indications. This "universal receptor" with antibody-dependent targeting approach,..."

Breast Cancer • Burkitt Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • HER2 Breast Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD20 • EGFR • HER-2 • PD-L1

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) - "Celularity Inc...announced today that it presented in vivo data from its T-cell therapy platform at this year’s ASCO Annual Meeting in Chicago. These data show that PT-CD16VS, Celularity’s T-Cell preclinical asset, has potent in vitro and in vivo activity and has the potential to be combined with various monoclonal antibodies to target multiple cancers...Celularity has adopted a 'universal receptor' approach to develop a platform of genetically modified T-cells expressing a proprietary CD16 to be combined with various approved antibodies to address multiple cancers and other conditions....Data demonstrating PT-CD16VSs activity in combination with trastuzumab against HER2-positive cancers has already been presented at AACR in April. These data further build on this to demonstrate much broader potential across multiple hematological and solid tumors."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells (GlobeNewswire) - "Celularity In...announced today that it will present in vivo data from its T-cell therapy platform at this year’s AACR Annual Meeting. These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024....The data in this study demonstrates that treatment with PT-CD16VS in combination with trastuzumab resulted in a significant reduction in tumor volume compared to treatment with trastuzumab alone, as well as with Enhertu alone, which is the current standard of care."

Preclinical • Oncology • Solid Tumor